Literature DB >> 26194310

Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.

Clifford R Jack1, Josephine Barnes2, Matt A Bernstein3, Bret J Borowski3, James Brewer4, Shona Clegg2, Anders M Dale4, Owen Carmichael5, Christopher Ching6, Charles DeCarli7, Rahul S Desikan8, Christine Fennema-Notestine9, Anders M Fjell10, Evan Fletcher7, Nick C Fox2, Jeff Gunter3, Boris A Gutman6, Dominic Holland4, Xue Hua6, Philip Insel11, Kejal Kantarci3, Ron J Killiany12, Gunnar Krueger13, Kelvin K Leung14, Scott Mackin15, Pauline Maillard7, Ian B Malone2, Niklas Mattsson16, Linda McEvoy8, Marc Modat17, Susanne Mueller18, Rachel Nosheny18, Sebastien Ourselin17, Norbert Schuff18, Matthew L Senjem3, Alix Simonson11, Paul M Thompson6, Dan Rettmann19, Prashanthi Vemuri3, Kristine Walhovd10, Yansong Zhao20, Samantha Zuk3, Michael Weiner21.   

Abstract

INTRODUCTION: Alzheimer's Disease Neuroimaging Initiative (ADNI) is now in its 10th year. The primary objective of the magnetic resonance imaging (MRI) core of ADNI has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders.
METHODS: We review the contributions of the MRI core from present and past cycles of ADNI (ADNI-1, -Grand Opportunity and -2). We also review plans for the future-ADNI-3.
RESULTS: Contributions of the MRI core include creating standardized acquisition protocols and quality control methods; examining the effect of technical features of image acquisition and analysis on outcome metrics; deriving sample size estimates for future trials based on those outcomes; and piloting the potential utility of MR perfusion, diffusion, and functional connectivity measures in multicenter clinical trials. DISCUSSION: Over the past decade the MRI core of ADNI has fulfilled its mandate of improving methods for clinical trials in AD and will continue to do so in the future.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADNI; Alzheimer's Disease Neuroimaging Initiative; Alzheimer's disease; Diffusion; MRI; Neuroimaging; Perfusion; Resting functional MRI

Mesh:

Substances:

Year:  2015        PMID: 26194310      PMCID: PMC4523217          DOI: 10.1016/j.jalz.2015.05.002

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  168 in total

Review 1.  Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.

Authors:  Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes.

Authors:  Gloria C Chiang; Philip S Insel; Duygu Tosun; Norbert Schuff; Diana Truran-Sacrey; Sky Raptentsetsang; Clifford R Jack; Michael W Weiner
Journal:  Radiology       Date:  2011-04-05       Impact factor: 11.105

3.  Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau.

Authors:  Rahul S Desikan; Linda K McEvoy; Wesley K Thompson; Dominic Holland; James B Brewer; Paul S Aisen; Reisa A Sperling; Anders M Dale
Journal:  Arch Neurol       Date:  2012-06

Review 4.  Clinically asymptomatic vascular brain injury: a potent cause of cognitive impairment among older individuals.

Authors:  Charles DeCarli
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

5.  The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment.

Authors:  R Scott Mackin; Philip Insel; Duygu Tosun; Susanne G Mueller; Norbert Schuff; Diana Truran-Sacrey; Sky T Raptentsetsang; Jun-Young Lee; Clifford R Jack; Paul S Aisen; Ronald C Petersen; Michael W Weiner
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

6.  Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI.

Authors:  Val J Lowe; Patrick J Peller; Stephen D Weigand; Catalina Montoya Quintero; Nirubol Tosakulwong; Prashanthi Vemuri; Matthew L Senjem; Lennon Jordan; Clifford R Jack; David Knopman; Ronald C Petersen
Journal:  Neurology       Date:  2013-05-03       Impact factor: 9.910

7.  Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection.

Authors:  Kelvin K Leung; Matthew J Clarkson; Jonathan W Bartlett; Shona Clegg; Clifford R Jack; Michael W Weiner; Nick C Fox; Sébastien Ourselin
Journal:  Neuroimage       Date:  2009-12-23       Impact factor: 6.556

8.  Algorithms, atrophy and Alzheimer's disease: cautionary tales for clinical trials.

Authors:  Nick C Fox; Gerard R Ridgway; Jonathan M Schott
Journal:  Neuroimage       Date:  2011-02-04       Impact factor: 6.556

9.  Rates of decline in Alzheimer disease decrease with age.

Authors:  Dominic Holland; Rahul S Desikan; Anders M Dale; Linda K McEvoy
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

10.  Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls.

Authors:  Josephine Barnes; Owen T Carmichael; Kelvin K Leung; Christopher Schwarz; Gerard R Ridgway; Jonathan W Bartlett; Ian B Malone; Jonathan M Schott; Martin N Rossor; Geert Jan Biessels; Charlie DeCarli; Nick C Fox
Journal:  Neurobiol Aging       Date:  2013-03-21       Impact factor: 4.673

View more
  54 in total

1.  Fractional anisotropy derived from the diffusion tensor distribution function boosts power to detect Alzheimer's disease deficits.

Authors:  Talia M Nir; Neda Jahanshad; Julio E Villalon-Reina; Dmitry Isaev; Artemis Zavaliangos-Petropulu; Liang Zhan; Alex D Leow; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Magn Reson Med       Date:  2017-03-07       Impact factor: 4.668

2.  Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease.

Authors:  Michael Ewers; Nicolai Franzmeier; Marc Suárez-Calvet; Estrella Morenas-Rodriguez; Miguel Angel Araque Caballero; Gernot Kleinberger; Laura Piccio; Carlos Cruchaga; Yuetiva Deming; Martin Dichgans; John Q Trojanowski; Leslie M Shaw; Michael W Weiner; Christian Haass
Journal:  Sci Transl Med       Date:  2019-08-28       Impact factor: 17.956

Review 3.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

4.  Whole mouse brain connectomics.

Authors:  G Allan Johnson; Nian Wang; Robert J Anderson; Min Chen; Gary P Cofer; James C Gee; Forrest Pratson; Nicholas Tustison; Leonard E White
Journal:  J Comp Neurol       Date:  2018-11-23       Impact factor: 3.215

5.  Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter.

Authors:  Alexis Moscoso; Michel J Grothe; Michael Schöll
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-21       Impact factor: 9.236

6.  Fast predictive simple geodesic regression.

Authors:  Zhipeng Ding; Greg Fleishman; Xiao Yang; Paul Thompson; Roland Kwitt; Marc Niethammer
Journal:  Med Image Anal       Date:  2019-06-12       Impact factor: 8.545

7.  Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.

Authors:  Niklas Mattsson; Nicholas C Cullen; Ulf Andreasson; Henrik Zetterberg; Kaj Blennow
Journal:  JAMA Neurol       Date:  2019-07-01       Impact factor: 18.302

8.  In vivo magnetic resonance imaging and spectroscopy. Technological advances and opportunities for applications continue to abound.

Authors:  Peter van Zijl; Linda Knutsson
Journal:  J Magn Reson       Date:  2019-07-09       Impact factor: 2.229

9.  Multimodal imaging in familial FTLD: phenoconversion and planning for the future.

Authors:  Bradley F Boeve; Howard J Rosen
Journal:  Brain       Date:  2019-01-01       Impact factor: 13.501

10.  Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.

Authors:  Shannon L Risacher; Wesley H Anderson; Arnaud Charil; Peter F Castelluccio; Sergey Shcherbinin; Andrew J Saykin; Adam J Schwarz
Journal:  Neurology       Date:  2017-10-25       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.